Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomasHannah K. Jaeger(National Cancer Institute), Robert Yarchoan(National Cancer Institute)Scientific ReportsJuly 18, 202310.1038/s41598-023-38156-zCited by 4SaveCiteExport RISWatch citationsRelated PapersPomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2|PLoS Pathogens|2021|39